Immunovant Competitors, Revenue, Alternatives and Pricing

Claim your profile


Total Funding:N/A
Lead Investor(s):N/A

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Immunovant's estimated annual revenue is currently $12.1M per year.(?)
  • Immunovant's estimated revenue per employee is $155,000

Employee Data

  • Immunovant has 78 Employees.(?)
  • Immunovant grew their employee count by 129% last year.
  • Immunovant currently has 3 job openings.

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Our investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection. We have initiated Phase 2 studies in two target indications: myasthenia gravis (MG) and Gravesᅢᄁ¬ツᆲ¬トᄁ ophthalmopathy (GO). We anticipate that we will submit an IND in one additional indication, warm autoimmune hemolytic anemia (WAIHA), in the second half of 2019. We plan to continue expanding our pipeline with innovative therapies that could transform the lives of patients living with autoimmune diseases. *Please note that all applications should be placed through our official career site: We will never email you to ask for personal information such as SSN or banking information nor would we ever ask a candidate for payment of any kind as part of the hiring or onboarding process.